Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

Primary immune thrombocytopenia is an autoimmune disease associated with a reduced
peripheral blood platelet count. The phenotype is variable with some patients suffering no …

Background A single-group, phase 1–2 study indicated that eltrombopag improved the
efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin …

Background Rilzabrutinib, an oral, reversible covalent inhibitor of Bruton's tyrosine kinase,
may increase platelet counts in patients with immune thrombocytopenia by means of dual …

Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor
agonist (TPO‐RA) but not another. Limited data are available describing outcomes in …

Inflammation has been described for two millennia, but cellular aspects and the paradigm
involving different mediators have been identified in the recent century. Two main groups of …

Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy,
autoimmune disease, bone marrow disorders, pathologic conditions associated with …

Thrombocytopenia, defined as a platelet count< 150,000/μL, is the most common
complication of advanced liver disease or cirrhosis with an incidence of up to 75%. A …

Management of immune thrombocytopenia (ITP) during pregnancy can be challenging
because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which …

Thrombopoietin regulates platelet production through activation of the thrombopoietin
receptor (TPO-R). TPO-R agonists (TPO-RAs) are available to treat thrombocytopenia in …